Triptolide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Triptolide
Accession Number
DB12025
Type
Small Molecule
Groups
Investigational
Description

Triptolide has been used in trials studying the treatment of HIV, Crohn's Disease, Intestinal Diseases, Gastrointestinal Diseases, and Digestive System Diseases, among others.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
19ALD1S53J
CAS number
38748-32-2
Weight
Average: 360.406
Monoisotopic: 360.157288493
Chemical Formula
C20H24O6
InChI Key
DFBIRQPKNDILPW-CIVMWXNOSA-N
InChI
InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1
IUPAC Name
(1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-(propan-2-yl)-3,6,10,16-tetraoxaheptacyclo[11.7.0.0^{2,4}.0^{2,9}.0^{5,7}.0^{9,11}.0^{14,18}]icos-14(18)-en-17-one
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Triptolide is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Triptolide is combined with 5-androstenedione.Experimental, Illicit
AbciximabTriptolide may increase the anticoagulant activities of Abciximab.Approved
AcebutololTriptolide may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Triptolide.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Triptolide is combined with Acemetacin.Approved
AcenocoumarolTriptolide may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Triptolide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Triptolide.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Triptolide.Approved, Vet Approved
AclarubicinTriptolide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Triptolide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Triptolide is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Alendronic acid.Approved
AliskirenTriptolide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Alminoprofen.Experimental
AlprenololTriptolide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Triptolide.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Amcinonide.Approved
AmikacinTriptolide may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTriptolide may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinTriptolide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTriptolide may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Triptolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Triptolide is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Triptolide is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Triptolide is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Triptolide.Investigational
annamycinTriptolide may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Triptolide.Approved
Antithrombin III humanTriptolide may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTriptolide may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Triptolide is combined with Apocynin.Investigational
ApramycinTriptolide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Triptolide.Approved, Investigational
ArbekacinTriptolide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTriptolide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTriptolide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTriptolide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Triptolide is combined with Atamestane.Investigational
AtenololTriptolide may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Triptolide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triptolide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Triptolide.Approved
BalsalazideTriptolide may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Triptolide.Investigational
BecaplerminTriptolide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Triptolide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTriptolide may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTriptolide may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Triptolide.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Triptolide is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Triptolide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Triptolide is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Triptolide.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Triptolide is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Triptolide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Betamethasone.Approved, Vet Approved
BetaxololTriptolide may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Triptolide.Approved, Investigational
BevantololTriptolide may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Triptolide is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Triptolide.Approved, Investigational
BisoprololTriptolide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTriptolide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTriptolide may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Triptolide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Triptolide is combined with Bucillamine.Investigational
BucindololTriptolide may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Triptolide is combined with Bufexamac.Experimental
BufuralolTriptolide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Bumadizone.Experimental
BumetanideTriptolide may decrease the diuretic activities of Bumetanide.Approved
BupranololTriptolide may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Triptolide.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Triptolide.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Triptolide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Triptolide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Triptolide.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Triptolide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Triptolide.Approved, Vet Approved, Withdrawn
CarteololTriptolide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTriptolide may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Triptolide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Triptolide.Approved, Investigational
CeliprololTriptolide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTriptolide may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Triptolide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Triptolide.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Triptolide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Triptolide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Triptolide.Approved
CinoxacinTriptolide may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidTriptolide may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Triptolide is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Triptolide is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Triptolide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Triptolide.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Triptolide.Vet Approved
CloranololTriptolide may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Triptolide.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Triptolide is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Triptolide is combined with Cortisone acetate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Triptolide.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Triptolide.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Triptolide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Triptolide.Approved, Investigational
CyclosporineTriptolide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Triptolide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Triptolide.Investigational
Dabigatran etexilateTriptolide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTriptolide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTriptolide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTriptolide may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinTriptolide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Triptolide is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Triptolide is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Triptolide.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Triptolide.Approved
DesirudinTriptolide may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Triptolide.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Triptolide is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Triptolide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Triptolide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Triptolide is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Triptolide.Approved, Investigational
DextranTriptolide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Triptolide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Triptolide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Triptolide may increase the anticoagulant activities of Dextran 75.Approved
DibekacinTriptolide may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Triptolide.Approved, Vet Approved
DicoumarolTriptolide may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Triptolide is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triptolide.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Triptolide is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Triptolide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Triptolide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Triptolide.Approved
DihydrostreptomycinTriptolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Triptolide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Triptolide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Triptolide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triptolide.Approved, Investigational
DoxorubicinTriptolide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTriptolide may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Triptolide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Triptolide.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Triptolide.Investigational
Edetic AcidTriptolide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTriptolide may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Triptolide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Triptolide.Approved
EnoxacinTriptolide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTriptolide may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Triptolide.Experimental
EpanololTriptolide may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Triptolide.Approved
EpirubicinTriptolide may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTriptolide may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Triptolide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Triptolide.Approved
EquileninThe risk or severity of adverse effects can be increased when Triptolide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Triptolide is combined with Equilin.Approved
EsmololTriptolide may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Triptolide is combined with Estrone sulfate.Approved
Etacrynic acidTriptolide may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Triptolide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Triptolide is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTriptolide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Triptolide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Triptolide.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Triptolide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Triptolide.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Triptolide.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Triptolide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Triptolide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Triptolide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Triptolide.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Triptolide is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Feprazone.Experimental
Ferulic acidTriptolide may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Triptolide.Approved, Investigational
FingolimodTriptolide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinTriptolide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Triptolide.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fludrocortisone.Approved
FluindioneTriptolide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTriptolide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Triptolide.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Triptolide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Triptolide.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Triptolide.Approved, Nutraceutical, Vet Approved
FondaparinuxTriptolide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTriptolide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Triptolide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Triptolide is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Triptolide.Approved
FramycetinTriptolide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideTriptolide may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Triptolide.Investigational
GabexateTriptolide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTriptolide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTriptolide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Triptolide.Approved, Withdrawn
GemifloxacinTriptolide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTriptolide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTriptolide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATriptolide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Triptolide.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Triptolide.Experimental
GPX-150Triptolide may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinTriptolide may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Triptolide is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Triptolide is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Triptolide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Triptolide is combined with HE3286.Investigational
HeparinTriptolide may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Triptolide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Triptolide.Approved, Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Triptolide is combined with Higenamine.Investigational
HydralazineTriptolide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Triptolide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Triptolide.Approved, Investigational
Hygromycin BTriptolide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Triptolide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Triptolide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Triptolide.Approved
IdarubicinTriptolide may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxTriptolide may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Triptolide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Triptolide.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Triptolide is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Triptolide.Approved
IndenololTriptolide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Triptolide is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Triptolide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Triptolide.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Triptolide.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Triptolide.Investigational
INNO-206Triptolide may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Triptolide.Approved, Investigational
IsepamicinTriptolide may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Triptolide.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Triptolide is combined with Istaroxime.Investigational
KanamycinTriptolide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Triptolide.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Triptolide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Triptolide.Approved
LabetalolTriptolide may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Triptolide.Experimental
LandiololTriptolide may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Triptolide.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Triptolide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Triptolide is combined with Leflunomide.Approved, Investigational
LepirudinTriptolide may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTriptolide may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololTriptolide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTriptolide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Triptolide.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Triptolide.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Triptolide is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Triptolide.Approved
LonazolacThe risk or severity of adverse effects can be increased when Triptolide is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Triptolide.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Triptolide.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Triptolide is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Triptolide.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Triptolide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Triptolide.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Triptolide.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Triptolide.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Triptolide.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Triptolide is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triptolide.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Triptolide.Approved
MelagatranTriptolide may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Triptolide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Triptolide.Approved, Vet Approved
MepindololTriptolide may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineTriptolide may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Triptolide.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Triptolide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Triptolide.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Triptolide.Experimental
MetipranololTriptolide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Triptolide.Approved
MetoprololTriptolide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTriptolide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinTriptolide may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Triptolide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Triptolide is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Triptolide.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Triptolide.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Triptolide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triptolide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Triptolide.Approved
NadololTriptolide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTriptolide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTriptolide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Triptolide.Approved
Nalidixic AcidTriptolide may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Triptolide.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Triptolide is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Triptolide is combined with NCX 1022.Investigational
NeamineTriptolide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTriptolide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTriptolide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTriptolide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Triptolide.Approved
NetilmicinTriptolide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Triptolide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Triptolide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Triptolide is combined with Nitroaspirin.Investigational
NorfloxacinTriptolide may increase the neuroexcitatory activities of Norfloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Triptolide.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Triptolide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triptolide.Approved
OlsalazineTriptolide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Triptolide is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Triptolide.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Triptolide.Vet Approved
OtamixabanTriptolide may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Triptolide.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Triptolide.Approved
Oxolinic acidTriptolide may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTriptolide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Triptolide.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptolide.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Triptolide.Approved
ParomomycinTriptolide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Parthenolide.Investigational
PazufloxacinTriptolide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTriptolide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTriptolide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTriptolide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateTriptolide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Triptolide.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Triptolide.Experimental
PhenindioneTriptolide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTriptolide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Triptolide.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triptolide.Approved, Investigational
PindololTriptolide may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidTriptolide may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinTriptolide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTriptolide may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Triptolide.Approved, Investigational
Piromidic acidTriptolide may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Triptolide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Pirprofen.Experimental
Platelet Activating FactorTriptolide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTriptolide may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinTriptolide may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Triptolide.Approved
PractololTriptolide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Triptolide.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Triptolide is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Triptolide is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Triptolide is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Triptolide is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Triptolide can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Triptolide is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Triptolide.Approved, Investigational
PropranololTriptolide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Triptolide.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Triptolide.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Triptolide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Triptolide.Vet Approved
Protein CTriptolide may increase the anticoagulant activities of Protein C.Approved
Protein S humanTriptolide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTriptolide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTriptolide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Triptolide.Investigational
PuromycinTriptolide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Triptolide.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Triptolide.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Triptolide is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Triptolide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Triptolide.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Triptolide.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Triptolide.Approved, Experimental, Investigational
ReviparinTriptolide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTriptolide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Triptolide.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Risedronate.Approved, Investigational
RivaroxabanTriptolide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Triptolide.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Triptolide.Approved
RosoxacinTriptolide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Triptolide.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Triptolide.Approved
RufloxacinTriptolide may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinTriptolide may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Triptolide.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Triptolide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Triptolide.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Triptolide.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Triptolide.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Triptolide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Triptolide.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Triptolide is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Triptolide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Triptolide is combined with Serrapeptase.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Triptolide.Approved
SisomicinTriptolide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTriptolide may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Triptolide.Approved
SotalolTriptolide may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTriptolide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTriptolide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinTriptolide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Triptolide.Approved
SpironolactoneTriptolide may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Triptolide.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Triptolide.Investigational
StreptomycinTriptolide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTriptolide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Triptolide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Triptolide.Approved
SulodexideTriptolide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Triptolide.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Triptolide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Triptolide is combined with Suxibuzone.Experimental
TacrolimusTriptolide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Triptolide.Approved
TalinololTriptolide may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Triptolide.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Triptolide.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Triptolide.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Triptolide.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Triptolide is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Triptolide.Approved, Investigational
TemafloxacinTriptolide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Triptolide.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Triptolide is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Triptolide is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Triptolide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Triptolide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Triptolide.Approved
TertatololTriptolide may decrease the antihypertensive activities of Tertatolol.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Triptolide.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Triptolide.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTriptolide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Triptolide is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Triptolide is combined with Tixocortol.Approved
TobramycinTriptolide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibTriptolide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Triptolide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Triptolide.Approved
TorasemideTriptolide may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Triptolide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Triptolide.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Triptolide.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Triptolide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Triptolide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triptolide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTriptolide may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Triptolide is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Triptolide.Approved, Vet Approved
TrovafloxacinTriptolide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTriptolide may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Triptolide is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Triptolide.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Triptolide.Investigational, Withdrawn
ValrubicinTriptolide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Triptolide.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Triptolide.Approved
WarfarinTriptolide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTriptolide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Triptolide.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triptolide.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Triptolide.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Triptolide.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Triptolide is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Triptolide.Withdrawn
Zoptarelin doxorubicinTriptolide may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinTriptolide may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Triptolide.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C09204
PubChem Compound
107985
PubChem Substance
347828340
ChemSpider
97099
BindingDB
50241049
ChEBI
9747
ChEMBL
CHEMBL463763

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV)1
2, 3Unknown StatusTreatmentCrohn's Disease (CD) / Digestive System Diseases / Gastrointestinal Diseases / Inflammatory Bowel Diseases (IBD) / Intestinal Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.886 mg/mLALOGPS
logP1.22ALOGPS
logP1.33ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)12.54ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area84.12 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity87.26 m3·mol-1ChemAxon
Polarizability37.14 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0429000000-1df7fd8b89c25073ab2d

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxepanes. These are compounds containing an oxepane ring, which is a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxepanes
Sub Class
Not Available
Direct Parent
Oxepanes
Alternative Parents
Butenolides / Enoate esters / Secondary alcohols / Lactones / Cyclic alcohols and derivatives / Oxacyclic compounds / Monocarboxylic acids and derivatives / Epoxides / Dialkyl ethers / Organic oxides
show 2 more
Substituents
Oxepane / 2-furanone / Cyclic alcohol / Dihydrofuran / Alpha,beta-unsaturated carboxylic ester / Enoate ester / Carboxylic acid ester / Lactone / Secondary alcohol / Monocarboxylic acid or derivatives
show 12 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
oxacycle (CHEBI:9747) / Diterpenoids (C20) (C09204)

Drug created on October 20, 2016 15:12 / Updated on November 09, 2017 05:01